Hints and tips:
...The payday would mark the second time Mr Hantson has cashed in by selling a pharma company he runs, following Shire’s $32bn takeover of US drugmaker Baxalta in 2016....
...Takeda Pharmaceuticals, which closed a £46bn deal for Irish drugmaker Shire last year, is in talks to sell its domestic over-the counter medicine business for several billion dollars to reduce its debt....
...After having its own deal to move to Ireland — through a 2014 takeover of Shire — blocked by policy changes from the Obama administration, the Chicago-based company has looked elsewhere....
...The overall costs on the deal rival the near $1bn that Japanese pharmaceutical group Takeda spent on its purchase of Shire last year, although it is dwarfed by the roughly $2bn of expenses and fees paid...
...Christophe Weber is racing to win backing for Japan’s largest-ever outbound takeover, which would catapult the Osaka-based drugmaker into the ranks of the world’s biggest pharmaceutical companies....
...Allergan, one of the most prolific dealmakers in the pharmaceutical sector, said on Thursday it was considering a return to the acquisition trail....
...If completed, it would rank as one of the industry’s biggest, and mark a significant moment in the evolution of Japan Inc as a global dealmaker....
...Allergan said it had not yet made an offer to Shire....
...Earlier this week, Shire agreed to sell its oncology business for $2.4bn in cash to Servier, a French pharmaceutical group....
...Japanese pharma group Takeda weighs bid for Shire In the latest sign of the revived appetite for dealmaking among drugmakers, Japan’s Takeda Pharmaceutical indicated its interest in buying Shire, the UK-listed...
...The two critiqued Allergan’s “arbitrary debt reduction target” as it pursues M&A, including its consideration of a bid for Shire, which it subsequently abandoned....
...The company, which recently ruled itself out of a bidding war for Irish drugmaker Shire, generated adjusted earnings of $3.74 per share on revenues of $3.67bn....
...The latest acquisition contributes to a record year for Japanese outbound deals, led by Takeda Pharmaceutical’s £46bn agreement to buy Irish drugmaker Shire in April....
...In 2014, investors, including Paulson & Co, suffered paper losses after US pharmaceuticals group AbbVie walked away from its £32bn deal to buy Shire....
...assembled its £46bn bid for Shire....
...Last week, Japan’s Takeda Pharmaceutical reached a preliminary agreement to buy Irish drugmaker Shire for about £46bn in a deal that bankers predicted was a portent of things to come....
...Takeda/Shire $65bn APRIL 2018 Takeda Pharmaceutical reaches a preliminary agreement to buy Irish drugmaker Shire for $65bn in a deal that could spark more M&A in the sector Yet as industries consolidate...
...The share price charts of Bioverativ since its spin-off from Biogen, and Shire after its acquisition of Baxalta, show that Hemlibra is a threat the market takes seriously....
...The combined value of those deals — which include Takeda Pharmaceutical’s ¥7tn planned takeover of Shire — was around ¥11.7tn....
...On Friday Shire said it was on track to achieve its target of $700m of cost savings from the acquisition....
...Some pharmaceutical groups implemented much larger increases....
...In the latest sign of how eager boardrooms are sparking a record number of “megadeals”, Japan’s top drugmaker Takeda revealed it was weighing a $40bn takeover of Irish rival Shire....
...The most high-profile recent mis-step was a big bet on drugmaker Valeant Pharmaceuticals....
...This included Mydayis, an ADHD drug to treat adults and for which Shire recently received regulatory approval....
...The chief executive of Shire has questioned investors’ valuation of his company, arguing the potential of a number of promising drugs has yet to be factored into its share price....
International Edition